Cyprus to take advantage of the European Cancer Plan, Commissioner Kyriakidou said
It is unacceptable, in 2022, that the way of diagnosis, treatment and survival of a cancer patient depends on the country he/she lives in Europe, said the European Commission's Health and Food Safety Commissioner, Stella Kyriakidou, noting that Cyprus should take full advantage of what the European Cancer Plan offers for the benefit of its patients.
The European Commissioner was speaking, on Friday evening, at the opening ceremony of the 4th Cyprus Oncology Conference on "Making Progress in Cancer Treatment through Research, Innovation and Intersectoral Cooperation", organised in Limassol by the Cyprus Cancer Society and the Cyprus Oncology Society.
As Kyriakidou said, today cancer rates are particularly high in the EU and it is the leading cause of death of Europeans under 65 years of age, affecting lives and families and putting pressure on health systems.
"There is absolutely no doubt that this must change. Several key initiatives of the Cancer Plan contribute to these efforts, for the benefit of all EU citizens, including my country," she added.
Describing this Plan as one of the most important to be implemented by the European Commission, Kyriakidou said that every action is within the targets set and "this shows the importance that the Commission has given to its implementation."
In her speech, Ms. Kyriakidou referred to three of the Plan's research and innovation actions, the first being the Cancer Knowledge Centre, launched in June 2021, which "helps coordinate scientific and technical initiatives related to cancer at EU level".
The second action, he continued, is the creation of the Cancer Inequalities Register, "which identifies trends, inequalities and inefficiencies, related to cancer prevention and care in Europe." "It is totally unacceptable that, in 2022, diagnosis, treatment and survival depend on where one lives in the EU," he added, suggesting that "this independent project to collect data and provide evidence offers valuable guidance to policy makers as to areas where improvements need to be made."
Regarding the 3rd action, the European Cancer Imaging Initiative, the Commissioner said that preparations are being made for its launch in early 2023 and through it, all stakeholders, working across hospitals, research and innovation, will be able to access an EU atlas of cancer-related images." This, she said, will lead to the optimisation of personalised medicine and support innovative solutions in diagnosis and treatment.
Saying that innovation has a key role to play in joint efforts "to change the reality of cancer", Stella Kyriakidou said this role became more crucial through the Covid-19 pandemic, as the challenges revealed what needs to be done to strengthen cancer care and maintain a resilient health system.
He noted that during the pandemic there were delays in screening, discontinued diagnoses and treatments and reduced access to medicines and monitoring, and it is estimated that nearly one million European citizens missed appointments for their screenings. Also, she continued, the pandemic revealed weaknesses in health systems, where more financial support was needed and where priorities had not been given.
In her report on Cyprus, Commissioner Kyriakidou said that overall, the health situation of citizens is at a higher level than the EU average, progress has been made in tackling diseases and the mortality rate, from cancer, has remained stable in recent years, below the EU average.
At the same time, however, she indicated that cancer still accounts for almost a quarter of all deaths in Cyprus and expressed her confidence that much more can be done, especially in the area of prevention.
"We know that early diagnosis saves lives and we need to focus on early detection so that we can then successfully offer treatments," she said, noting that according to figures from the Ministry of Health, only 3 in 10 women are screened for breast cancer, while the rest of Europe records twice that number (6 in 10 women).
He stressed, however, that the new EU Screening Programme sets a target for the first time to cover 90% of the eligible EU population in breast, cervical and colorectal cancer screening.
In this context, he continued, the European Commission has proposed new European guidelines on screening, which are being discussed by the competent ministries of the Member States, expressing the hope for a positive development.
Among other things, Commissioner Kyriakidou recalled that the EU4Health programme has a budget of €5.2 billion until 2027, of which €30 million will be allocated to support and monitor innovative approaches to screening for prostate, lung and stomach cancer.
"Further recognising the importance of research and innovation for screening, the EU Horizon cancer mission has allocated another €60 million to develop new methods and technologies for screening and early detection of cancer," she added.
In total, more than €140 million will be invested to support Member States in developing new cancer screening programmes.Kyriakidou stressed that these funding opportunities should not be lost and expressed the hope that Cyprus will take full advantage of what is offered through the available European projects.
She also said that Cyprus' National Cancer Strategy is interwoven with the European Cancer Plan and policy making, both at national and European level, can work in parallel and in synergy so that there is a common benefit.
"Together we can make a difference and we have a unique opportunity," he said, stressing that this is an extraordinary moment in which "we have a European Cancer Plan with a €4 billion budget, a European Commission committed to enforce and implement it, 27 Member States supporting it and a European Parliament that has made it a priority."
Source: CNA
Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times
Source